The purpose of this study is to see how different forms of a medicine called PF-08049820 move through the body when taken by mouth. The scientists want to see: * How well is the medicine absorbed when it's made in different ways (fast vs. slow release) * If eating a high-fat meal changes how the medicine moves through the body The results of this study will help decide which version of the medicine is best for future studies. This study is seeking participants who: * are men and women who can't have children * are 18 years or older * weigh more than 99 pounds (45 kg) * have a healthy body weight (not too low or too high) * are generally healthy with no serious medical problems. People with serious health problems, recent drug use, or who had certain vaccines recently cannot join. * are willing to follow all the study rules Each participant will try 5 different versions of the medicine, one at a time. There will be 3 days between each dose to make sure the medicine is out of the system. The medicine will be tested in different forms: * Immediate-release tablet (works quickly) * Short-release tablet (works slowly) * Long-release tablet (works even slower) Some versions will be taken without food, and others after eating a high-fat meal. After each dose, doctors will take blood samples for up to 72 hours to see how the medicine moves through the body. The whole study will take about 6 to 11 weeks and participants will stay overnight in the clinic for about 17 days.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
Administered orally
Administered orally
Administered orally
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, United States
Pharmacokinetics (PK): Plasma Area Under the Concentration Versus Time Curve (AUC) of PF-08049820 in the fasted state
Time frame: Pre-dose until 72 hours post dose
PK: Plasma Maximum Concentration (Cmax) of PF-08049820 in the fasted state
Time frame: Pre-dose until 72 hours post dose
PK: Plasma Area Under the Concentration Versus Time Curve (AUC) of PF-08049820 in the fed state
Time frame: Pre-dose until 72 hours post dose
PK: Plasma Maximum Concentration (Cmax) of PF-08049820 in the fed state
Time frame: Pre-dose until 72 hours post dose
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: First dose, up to follow up visit (28-35 days post last dose)
Number of Participants With Clinical Laboratory Abnormalities
Time frame: Baseline, up to Day 16
Number of Participants With Vital Signs Abnormalities
Time frame: Baseline, up to Day 16
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings
Time frame: Baseline, up to Day 16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.